Therapeutic compositions
First Claim
Patent Images
1. An iRNA duplex agent comprising a first and a second sequence, having a first monomer in the first sequence and a second monomer in the second sequence within the first 3, 4, 5, or 6 positions from either the 3′
- end or the 5′
end, wherein the first and second monomers are selected such thati) the first and second monomers are naturally occurring ribonucleotides or modified ribonucleotides having naturally occurring bases, wherein the ribonucleotide of the first monomer and the ribonucleotide of the second monomers, when occupying complementary sites that do not pair and have no substantial level of H-bonding, form a non canonical Watson-Crick pairing; and
ii) the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequence differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence,wherein the iRNA agent comprises a TT overhang sequence.
0 Assignments
0 Petitions
Accused Products
Abstract
This application relates to therapeutic siRNA agents and methods of making and using the agents.
-
Citations
13 Claims
-
1. An iRNA duplex agent comprising a first and a second sequence, having a first monomer in the first sequence and a second monomer in the second sequence within the first 3, 4, 5, or 6 positions from either the 3′
- end or the 5′
end, wherein the first and second monomers are selected such thati) the first and second monomers are naturally occurring ribonucleotides or modified ribonucleotides having naturally occurring bases, wherein the ribonucleotide of the first monomer and the ribonucleotide of the second monomers, when occupying complementary sites that do not pair and have no substantial level of H-bonding, form a non canonical Watson-Crick pairing; and ii) the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequence differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence, wherein the iRNA agent comprises a TT overhang sequence. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- end or the 5′
-
8. An iRNA duplex agent comprising a first and a second sequence, having a first monomer in the first sequence and a second monomer in the second sequence within the first 3, 4, 5, or 6 positions from either the 3′
- end or the 5′
end, wherein the first and second monomers are selected such thati) the first and second monomers are naturally occurring ribonucleotides or modified ribonucleotides having naturally occurring bases, wherein the ribonucleotide of the first monomer and the ribonucleotide of the second monomers, when occupying complementary sites that do not pair and have no substantial level of H-bonding, form a non canonical Watson-Crick pairing; and ii) the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequence differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence, represented by - View Dependent Claims (9, 10, 11, 12, 13)
- end or the 5′
Specification